Medarex Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Princeton NJ United States (1987)
Status: Acquired by Bristol-Myers Squibb (2009)

Organization Overview

First Clinical Trial
2004
NCT01510288
First Marketed Drug
1997
albuterol (proventil)
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Medarex

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anthrax (Phase 1)

Clostridium Infections (Phase 2)

Hodgkin Disease (Phase 2)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Mantle-Cell (Phase 1)

Melanoma (Phase 3)

Prostatic Neoplasms (Phase 1)

Sarcoma (Phase 2)

Sarcoma, Synovial (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 23
  • # of Trial APIs: 28